We have previously shown that variable region heavy chain (V H ) genes in FL commonly acquire sequence motifs by somatic mutation that serve as sites for N-glycosylation. 1 We further
showed that subsets of aggressive B NHL acquire sites 2 in contrast to sequences of myeloma, CLL and normal B cells where this is rare. 1 These data suggest positive selection and a critical role for the introduced glycosylation sites in the pathogenesis of FL.
To provide a context for interpreting our own data, we assessed V H gene usage in our own and published sequences.
3-8 Table 1 The incidence of novel N-glycosylation sites in the V genes of patients with follicular lymphoma
Letters to the Editor Analysis of the V H and/or V L genes in an extended cohort of 262 cases of FL revealed no significant bias compared to normal B cells. We next analysed matched V H and V L sequences to provide a complete view of the B-cell receptor obtained from biopsies after written informed consent of the patients. Sequence analysis of FL V genes shows that the most dramatic distinction to normal B cells lies in the accumulation of motifs available for addition of oligosaccharides. V H and V L sequences were examined for potential N-glycosylation sites with the motif Asn-X-Ser/Thr (N-X-S/T), where X could be any amino acid except Pro (Table 1) . Motifs using Asp, Glu, Leu or Trp as the middle amino acid X and when followed by Ser were included in this analysis even though they represent disfavoured amino acids where functional glycosylation at the protein level may be less likely. 9 Twenty-nine of 36 V H rearrangements and 20 of 44 V L rearrangements acquired new sites. Of note, the naturally occurring site in V4-34 appears irrelevant and is commonly lost in FL. The paired analysis of 33 FL shows that 94% of tumours acquire at least one and up to five novel potential Nglycosylation sites and of these 13 have sites in both V H and V L , 15 in V H alone and three in V L alone. A motif was not found in two cases. In case P32, it was likely due to an unusually low level of somatic hypermutation (SHM). We observed 1.0 and 1.1% mutation of V H and V L , respectively, compared to other FL (V H : mean 10.6%; V L mean 6.0%). In P39, motifs are present in some members of the clone, but perhaps have not yet assumed dominance. Here, we observed novel sites in the CDR3 of 3/12 of the V H clones and in the CDR1 and CDR3 of 1/11 and 3/11 of the V L clones, respectively (Figure 1) . Creation of additional motifs by SHM in subclones was also evident in cases with motifs in the consensus sequences found in all clones. V H genes from four cases (P2, P12, P16, P21) had additional motifs arising in this way, affecting on average 14% of clones. Similarly, V L genes from a further four cases (three in V k (P8, P17, P42) and one in V l (P23)) had additional sites which were shared by 38% of clones. Overall, nine of 44 (21%) tumours continued to accumulate N-glycosylation sites as a result of ongoing SHM.
The distribution of novel N-glycosylation sites in the V H and V L gene sequences is shown in Figure 2a . The majority (87%) of sites in V H were located in the complementarity determining regions (CDRs): CDR2 (n ¼ 22) 4CDR3 (n ¼ 11) 4CDR1 (n ¼ 5). Framework regions (FRs) acquired fewer sites (n ¼ 6).
Figure 1
The accumulation of N-glycosylation sites during ongoing SHM in P39. The V H and V L clones from P39 were analysed (FR1 to FR4) for N-glycosylation motifs introduced during ongoing SHM resulting in intraclonal heterogeneity. The consensus sequences of tumour-derived V H and V L from P39 do not feature a site. 
The location of N-glycosylation sites observed in the V H genes of our 29 FL was compared to other studies with published sequences from 69 FL. 5, 6, 8 Values are expressed for each region as a percentage of the total number of sites (n ¼ 141).
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No difference was found in the number or location of sites between tumours of different isotypes. For V L , the motifs are focused mainly in CDR3, with a notable absence in CDR2. No sites were found in FR2 in either V H or V L in keeping with the internal location of this region in the antibody protein. To broaden the analysis, the location of sites in the published V H genes of an additional 69 FL 5, 6, 8 were analysed (Figure 2b ). The focusing of V H sites within CDR2 and CDR3 (41 and 29% of sites, respectively) was confirmed. Considering also that in normal B cells with similar levels of SHM motifs are observed in Table 2 Analysis of somatic mutations giving rise to N-glycosylation motifs: a focus on V H CDR2
Letters to the Editor only a small minority of sequences, 1 it appears that the motifs in CDR3 of FL are acquired by SHM rather than by the VDJ (V H ) or VJ (V L ) recombination.
In all, 26 different N-glycosylation motifs were observed. The most commonly used was NIS, which was observed in nine (21%) of V H genes, but which was only seen once in V L . Other repeatedly used motifs included NIT (n ¼ 5), NSS, NTS, NYT and NLT (all n ¼ 4). The disfavoured motifs NDS, NLS and NWS were found in four FL and involved two V H genes and two V L genes, but in all cases additional sites were present in either the V gene itself or its partner chain. Motifs were created by a range of nucleotide changes. The codon for Asn (AAU or AAC) was generated by mutation rather than being derived from germline sequence in 41 of 45 (91%) instances. 'Starter' sequences for motif generation depended on the donor germline V H . For example, YIS present in V3-48 and V3-11 gene segments at CDR2 was mutated in six sequences to NIS and in two cases to NIT. Mutational changes of Ser to Asn were relatively common (12/45), likely reflecting the presence of a hot spot of SHM at codon 50 in CDR2 (see below). Other common amino-acid (aa) replacements in codon 1 affected Tyr (15/45) and Thr (6/45), where replacement mostly required one nucleotide change to generate the starter Asn. Acquisition of sites was indeed predominantly (73%) achieved by a single aa replacement to Asn at position 1 of the motif. At the nucleotide level, the first codon underwent mutations of one (68%), two (29%) and rarely three (2%) nucleotides. In a substantial proportion (24%), additional, non-essential aa replacements in codon 2 (n ¼ 4) or codon 3 (n ¼ 7) were found. It is interesting to note that unlike the Asn in codon 1, the C-terminal Ser of the motif was most commonly found either in the natural sequence (n ¼ 20) or mutated from Ser to Thr (n ¼ 6); 18 motifs therefore ended in Thr, of which only one-third were present in the germline sequence. A change of Thr to Ser was only observed once. Where codon 3 was mutated (42%), SHM had affected one (63%) or two (37%) nucleotide mutations. In all, 18% of sites were created through an essential aa replacement at both positions 1 and 3 of the motif, but only in a minority (9%) by an essential aa replacement at position 3 alone. A more detailed analysis of the generation of N-glycosylation sites in the V H CDR2 was performed and included sequences from cited references 5, 6, 8 (Table 2 ). All 47 sequences with CDR2 motifs used V H 3 (n ¼ 35) and V H 4 (n ¼ 12) genes. Here, 60% had acquired a site at aa position 50-52. Codon 50 is a recognized hotspot for SHM in both productively and non-productively rearranged alleles of normal B cells and affected B20% of cases. 10 A total of 60% of FL sequences showed a replacement mutation here (28/47). This may, in part, be explained by the relative over representation of the V H 3 genes and in particular V3-48, for which the majority of sites were generated by aa replacement at position 50. In contrast, there is no recognized hotspot for SHM at codon 52 of V H , 10 but we find that codon 52 is mutated in 21 of 34 cases. The high incidence of codon 52 changes in CDR2 motifs further point to selective pressure on FL to acquire N-glycosylation sites in their V genes. Eight further cases using the gene segments V3-11, V3-23 or V3-30 generated sites by a replacement mutation at codon 50, the majority (6/8) with an additional permissive mutation in codon 52. For segments V3-07, all sites were generated by the replacement of Lys to either Ser or Thr at position 52. For segments V3-15, all sites were generated by the replacement of Ser to Asn at position 52a. In the remaining gene segments, sites did not appear to focus to any one aa position. Strikingly in V L there is a complete absence of motifs in CDR2 in spite of a known hotspot for SHM in codon 52. This points to a selection against further acquisition of sites here, as in normal B cells CDR2 (and CDR1) appear to be preferentially subjected to SHM. 11 Other common hotspots for SHM such as codons 31, 55 or 82a were not used to generate novel sites and we observed no repeated location of sites in V L . Overall analysis of the affected codons provides further evidence for positive selection. Additionally, the accumulation of motifs in CDR3 of FL compared to normal B cells provides new data that this region in the V genes is affected by SHM, which had previously been difficult to show directly in the absence of a germline counterpart.
Using a 293F mammalian expression system, recombinant scFv proteins incorporating the paired V H and V L from eight FL were expressed and purified. We show that in all eight cases, the expressed tumour-derived scFv contains glycans, which are susceptible to enzymatic removal in vitro (Figure 3 ). Heterogeneity was also consistent with variable addition of carbohydrate. For example, P21, which has four N-glycosylation sites in V H and one in V L migrated much more slowly than P6, which has just one site in V H . This finding supports the conclusion that sites defined by molecular means are likely glycosylated in FL cells. Whether disfavoured motifs contribute to variable region glycosylation is difficult to assess at this point as in all cases additional motifs using a favoured aa sequence were detected.
The incidence of introduced motifs appears universal in somatically mutated FL, but the phenomenon is not confined to FL. We have also observed sites in a proportion (B40%) of cases of DLBCL, and commonly (82%) in endemic Burkitt's lymphoma. 2 However, sites are only occasionally seen in mutated CLL and multiple myeloma. The same is true for available sequences of normal B cells (memory B cells or plasma cells) with comparable levels of SHM to FL. 1 One conclusion might be that the added oligosaccharides have a role in survival or growth of B-cell malignancies in the germinal centre. With regard to FL, it is likely that the characteristic t(14;18) translocation occurs in the bone marrow during maturation of the B cells and clearly this alone does not confer tumorigenic behaviour since it is found in healthy individuals. However, retention of sIg expression is high in FL, pointing to a possible role for stimulation via the B-cell receptor in pathogenesis. The finding of functional N-glycosylation motifs suggests a strategy for the tumour cell to interact with a lectin in the germinal centre. This could replace the need for persistent antigen which would differ in every case and is an unlikely continuing Glycosylation of scFv proteins expressed in 293F cells. Tumour-derived V H and V L sequences from eight patients (P4, P6, P14, P21, P25, P27, P29 and P41) were assembled as single chain Fv (scFv), linked to a human kappa constant (Ck) region and cloned into the expression vector pcDNA3. Proteins were expressed using the FreeStylet293 expression system (Invitrogen), purified on a sheep anti-human free k chain column, separated by SDS-PAGE and visualized by staining with Coomassie blue. To remove N-linked carbohydrates, scFv-Ck proteins were treated with Peptide:N-glycosidase F ( þ ) (New England Biolabs).
stimulant. The ongoing stimulation via a substitute lectin could account for the ongoing somatic mutation. Our data support the concept that glycosylation could contribute to the development of FL. The characteristic t(14;18) chromosomal translocation may be only a first step to tumorigenesis, and we propose that the universal acquisition of N-glycosylation sites in the GC contributes a second critical factor. The nature of the added oligosaccharide is at present under investigation, with preliminary experiments suggesting an unusual composition (manuscript in preparation). If this is indeed a mechanism required for maintenance of FL, interruption would provide a clear therapeutic goal.
Several groups have recently reported the presence of a unique gain-of-function JAK2 point mutation (V617F) in the majority of cases of classic cMPD as well as in a minority of atypical MPDs and in occasional cases of AML. To date, this mutation has not been reported in normal controls, lymphoid disorders or in patients with secondary erythrocytosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In this study, we have analyzed bone marrow or peripheral blood samples from 349 patients (PV, n ¼ 84; ET, n ¼ 243; IMF, n ¼ 22) referred to our diagnostic service for cytogenetic analysis and/or exclusion of the BCR-ABL fusion from several hospitals in the north of Spain between 1996 and 2005. Our study group thus includes the largest series of ET cases reported to date for JAK2 analysis. DNA was extracted and tested for V617F by a sensitive amplification refractory mutation system as described previously. 6 Results were obtained from all samples and V617F was detected in 80, 62 and 68% of cases of PV, ET and IMF, respectively (Table 1) . These frequencies are comparable to other studies for PV and IMF, but somewhat higher than expected for ET, for which 23-57% of cases have been reported as V617F positive. Part of the reason for this is probably attributable to technical differences in the sensitivity of the V617F detection. Most other studies used sequencing, which can underestimate the proportion of positive patients, 2, 6 whereas allele-specific PCR assay is capable of detecting a mutation present in 1-2% of cells. 6 Of the 17 V617F-negative PV cases of our series, only two were female (P ¼ 0.044, contingency w 2 ¼ 4.058). This supports the previous observation of a significant male excess in mutation-negative PV cases. 6 In addition, a relative risk ratio estimate (RR ¼ 1.26; confidence interval 95% ¼ 1.04-1.52) of our data indicated that V617F is 26% more frequent in PV females compared to PV males (Table 1) .
PV and IMF are both considered to be clonal diseases, but for ET only approximately half of the cases are clonal, the remainder being polyclonal and therefore presumably reactive. It has been suggested 6 that the great majority of clonal ET cases must be V617F positive, but it remains to be determined if any V617F ET cases are also clonal. To address this question, we compared karyotypes between mutation-negative and mutationpositive cases. Of the 191 ET cases for whom cytogenetic analysis had been successfully performed, clonal cytogenetic abnormalities were observed in 11 of the 118 (9%) V617F-positive and five of the 73 (7%) V617F-negative patients ( Table 2) . Although the frequency of chromosome abnormalities
